- Home
- SYBT vs QURE Comparison
SYBT vs QURE Comparison
Compare SYBT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYBT | QURE |
|---|---|---|
| Founded | 1904 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | SYBT | QURE |
|---|---|---|
| Price | $69.73 | $20.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $80.33 | $56.25 |
| AVG Volume (30 Days) | 117.8K | ★ 1.9M |
| Earning Date | 01-27-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $390,560,000.00 | $15,751,000.00 |
| Revenue This Year | $16.90 | N/A |
| Revenue Next Year | $7.91 | $142.93 |
| P/E Ratio | $14.43 | ★ N/A |
| Revenue Growth | ★ 14.02 | N/A |
| 52 Week Low | $60.75 | $7.76 |
| 52 Week High | $83.83 | $71.50 |
Technical Indicators
Market Signals| Indicator | SYBT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 41.86 |
| Support Level | $66.98 | $24.37 |
| Resistance Level | $71.84 | $26.97 |
| Average True Range (ATR) | 1.90 | 2.05 |
| MACD | -0.05 | -0.21 |
| Stochastic Oscillator | 51.03 | 2.55 |
Price Performance
Historical ComparisonAbout SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.